- Philstar.com
- The Philippine Star
- Pilipino Star Ngayon
- The Freeman
- Pang-Masa
- Banat
- Interaksyon
- Coupons
Array ( [results] => Array ( [0] => Array ( [ArticleID] => 639200 [Title] => Roche drugs plus chemotherapy significantly improve rate of complete tumor disappearance [Summary] =>TEXAS – Roche recently announced results from the NEOSPHERE trial, a Phase II neoadjuvant study evaluating the effect of a novel combination regimen of pertuzumab and trastuzumab plus chemotherapy in women with early-stage HER2-positive breast cancer.
[DatePublished] => 2010-12-16 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [1] => Array ( [ArticleID] => 628535 [Title] => Roche drug approved as first-line blood cancer maintenance treatment [Summary] =>BASEL, Switzerland — Roche announced recently that the European Commission has approved the use of rituximab as a maintenance treatment for people suffering from follicular lymphoma, a common type of blood cancer, who have responded to initial induction therapy.
[DatePublished] => 2010-11-11 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
HAL BARRON
Array ( [results] => Array ( [0] => Array ( [ArticleID] => 639200 [Title] => Roche drugs plus chemotherapy significantly improve rate of complete tumor disappearance [Summary] =>TEXAS – Roche recently announced results from the NEOSPHERE trial, a Phase II neoadjuvant study evaluating the effect of a novel combination regimen of pertuzumab and trastuzumab plus chemotherapy in women with early-stage HER2-positive breast cancer.
[DatePublished] => 2010-12-16 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [1] => Array ( [ArticleID] => 628535 [Title] => Roche drug approved as first-line blood cancer maintenance treatment [Summary] =>BASEL, Switzerland — Roche announced recently that the European Commission has approved the use of rituximab as a maintenance treatment for people suffering from follicular lymphoma, a common type of blood cancer, who have responded to initial induction therapy.
[DatePublished] => 2010-11-11 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
abtest
EZ2/LVM - 16 31
SUERTRES - 4 7 8
4D Lotto - 4 2 7 1
6/45 Mega Lotto - 2 33 21 4 12 43
P26,743,701.00
6/55 Grand Lotto - 25 17 41 34 8 18
P29,700,000.00
- 12:00 am